Soluble CD146, a biomarker and a target for preventing resistance to anti-angiogenic therapy in glioblastoma

被引：0
|
作者：
Ahmad Joshkon
Emeline Tabouret
Wael Traboulsi
Richard Bachelier
Stéphanie Simoncini
Sandrine Roffino
Carine Jiguet-Jiglaire
Bassam Badran
Benjamin Guillet
Alexandrine Foucault-Bertaud
Aurelie S. Leroyer
Françoise Dignat-George
Olivier Chinot
Hussein Fayyad-Kazan
Nathalie Bardin
Marcel Blot-Chabaud
机构：
[1] Aix-Marseille University,Department of Neuro
[2] INSERM1263,Oncology
[3] INRAE1260,Laboratory of Cancer Biology and Molecular Immunology, Faculty of Science
[4] C2VN,Department of Radiopharmacy
[5] Aix-Marseille University,undefined
[6] APHM,undefined
[7] CNRS,undefined
[8] INP,undefined
[9] Service de Neuro-Oncologie CHU Timone,undefined
[10] Hôpitaux de Marseille,undefined
[11] CNRS,undefined
[12] ISM UMR 7287,undefined
[13] Aix-Marseille University,undefined
[14] Lebanese University,undefined
[15] La Timone University Hospital,undefined
[16] CERIMED,undefined
[17] Aix-Marseille University,undefined
来源：
Acta Neuropathologica Communications | / 10卷
关键词：
Soluble CD146; Biomarker; Therapeutic antibody; Bevacizumab; Glioblastoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
相关论文
共 50 条
  • [31] Mechanisms of Tumor Development and Anti-angiogenic Therapy in Glioblastoma Multiforme
    Onishi, Manabu
    Kurozumi, Kazuhiko
    Ichikawa, Tomotsugu
    Date, Isao
    NEUROLOGIA MEDICO-CHIRURGICA, 2013, 53 (11) : 755 - 763
  • [32] Endoglin (CD105) and proliferation index in recurrent glioblastoma treated with anti-angiogenic therapy
    Bastos, Antonio G. P.
    Carvalho, Bruno
    Silva, Roberto
    Leitao, Dina
    Linhares, Paulo
    Vaz, Rui
    Lima, Jorge
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [33] Identification of the hidden survival advantage for anti-angiogenic therapy in glioblastoma
    Nabors, Burt
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 (01) : 72 - 74
  • [34] Vascular Mimicry: A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma
    Angara, Kartik
    Borin, Thaiz F.
    Arbab, Ali S.
    TRANSLATIONAL ONCOLOGY, 2017, 10 (04): : 650 - 660
  • [35] Tumour angiogenesis, anti-angiogenic therapy and chemotherapeutic resistance
    Mander, K. A.
    Finnie, J. W.
    AUSTRALIAN VETERINARY JOURNAL, 2018, 96 (10) : 371 - 378
  • [36] Role of the tumor stroma in resistance to anti-angiogenic therapy
    Huijbers, Elisabeth J. M.
    van Beijnum, Judy R.
    Thijssen, Victor L.
    Sabrkhany, Siamack
    Nowak-Sliwinska, Patrycja
    Griffioen, Arjan W.
    DRUG RESISTANCE UPDATES, 2016, 25 : 26 - 37
  • [37] Resistance to chemotherapy and anti-angiogenic therapy in ovarian cancer
    Wieser, Verena
    Marth, Christian
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2019, 12 (02) : 144 - 148
  • [38] Resistance to chemotherapy and anti-angiogenic therapy in ovarian cancer
    Verena Wieser
    Christian Marth
    memo - Magazine of European Medical Oncology, 2019, 12 : 144 - 148
  • [39] Macrophages modulate adaptive resistance to anti-angiogenic therapy
    Dalton, Heather J.
    Pradeep, Sunila
    Armaiz-Pena, Guillermo N.
    Previs, Rebecca
    Davis, Ashley
    Rupaimoole, Rajesha
    Zand, Behrouz
    Hailemichael, Yared
    Overwijk, Willem W.
    Lopez-Berestein, Gabriel
    Sood, Anil K.
    CANCER RESEARCH, 2014, 74 (19)
  • [40] Angiogenic factors as potential drug target: Efficacy and limitations of anti-angiogenic therapy
    Gacche, Rajesh N.
    Meshram, Rohan J.
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2014, 1846 (01): : 161 - 179
12345